Lacosamid Fresenius Kabi

Lacosamide, the active ingredient in Lacosamid Fresenius Kabi, is a sodium channel blocker presented as an intravenous solution for intravenous use. It treats partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacosamid Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Lacosamide is an antiepileptic drug that modulates neuronal sodium channels to control seizure activity.

Partial‑onset seizures: reduces seizure frequency when used as adjunctive therapy. Adjunctive therapy for refractory focal epilepsy: improves seizure control in patients not responding to other agents. Secondary generalized seizures originating from focal onset: helps prevent spread of seizure activity.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Fatigue - Nausea - Headache - Blurred vision - Somnolence

Serious or Rare Side Effects: - PR interval prolongation or other cardiac conduction abnormalities - Suicidal ideation or behavior - Severe skin reactions such as Stevens‑Johnson syndrome - Respiratory depression - Anaphylactic reactions - Elevated liver enzymes

When using Lacosamid Fresenius Kabi, clinicians should observe several safety measures.

Monitor cardiac conduction: obtain baseline ECG and watch for PR interval changes. Assess renal function: adjust dosing in patients with impaired clearance. Evaluate hepatic status: use caution in severe liver disease. Avoid abrupt discontinuation: taper to prevent seizure worsening. Pregnancy considerations: use only if benefits outweigh potential risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lacosamide can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Co‑administration with other sodium‑channel blockers (e.g., carbamazepine) may increase cardiac risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole) can raise lacosamide plasma levels. - Strong CYP3A4 inducers (e.g., rifampin) may reduce therapeutic concentrations.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs (e.g., valproate) may require dose adjustments. - Alcohol may potentiate CNS depression. - Loop diuretics can affect renal clearance of lacosamide.